Mancheno-Valencia MA, Arenas-Guzmán R, Carrillo-Casas EM, Fernández-Martínez R, Toussaint-Caire S, Hernández-Castro R, Galván-Martínez I, Hajar-Serviansky T

Language: Spanish
References: 62
Page: 6-13
PDF size: 1139.43 Kb.

ABSTRACT

Nontuberculous mycobacteria cause a variety of diseases, especially in immunocompromised patients. It has been classified into four main clinical syndromes in humans: pulmonary disease, lymphadenitis, skin disease and disseminated disease. Among these, the chronic lung disease is the most common form. The incidence has increased over the years, both in hosts with impaired immunity as well as in healthy persons. Its prevalence has increased rapidly, in part because of diseases causing immunosuppression, such as AIDS (acquired immune deficiency syndrome) and also related to the availability of new technologies in laboratory methods, such as the high performance liquid chromatography, PCR (polymerase chain reaction) with restriction enzyme patterns, 16S rRNA (ribosomal ribonucleic acid) gene sequencing and DNA (deoxyribonucleic acid) homology studies which allow greater certainty in the recovery and identification of new species of nontuberculous mycobacteria.

REFERENCES

1. Godoy MJ, Orozco L, Hernández C, Da Mata O, De Waard J, González-Rico S. Identificación de micobacterias no tuberculosas: comparación de métodos bioquímicos y moleculares. Rev Soc Ven Microbiol. 2008; 28: 96-104.

2. Han XY, Sizer KC, Thompson EJ et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol. 2009; 191: 6067-6074.

3. Arenas R. Micobacteriosis atípicas. In: Arenas R, ed. Dermatología. Atlas, diagnóstico y tratamiento. 4th ed. México: Mc Graw Hill; 2009. pp. 395-397.

4. Falkinham JO. The changing pattern of nontuberculous mycobacterial disease. Can J Infect Dis. 2003; 14: 281-286.

5. Pinner M. Atypical acid fast microorganisms. Am Rev Tuberc. 1935; 32: 424-445.

6. Palenque E. Skin disease and nontuberculous atypical mycobacteria. Int J Dermatol. 2000; 39: 659-666.

7. Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev. 1996; 9: 177-215.

8. Saleeb P, Olivier KN. Pulmonary nontuberculous mycobacterial disease: new insights into risk factors for susceptibility, epidemiology, and approaches to management in immunocompetent and immunocompromised patients. Curr Infect Dis Rep. 2010; 12: 198-203.

9. Chapman JS. The ecology of the atypicalmycobacteria. Arch Environ Health. 1971; 22: 41-46.

10. Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009; 107: 356-367.

11. Baquero-Artigao F. Infección pediátrica por micobacterias no tuberculosas. An Pediatr (Barc). 2005; 62: 458-466.

12. Zakowski P, Fligiel S, Berlin GW, Johnson L, Jr. Disseminated Mycobacterium avium-intracellular infection in homosexual men dying of acquired immunodeficiency. JAMA. 1982; 248: 2980-2982.

13. Horsburgh CR, Jr. Epidemiology of mycobacterial diseases in AIDS. Res Microbiol. 1992; 143: 372-377.

14. Sanders JW, Walsh AD, Snider RL, Sahn EE. Disseminated Mycobacterium scrofulaceum infection: a potentially treatable complication of AIDS. Clin Infect Dis. 1995; 20: 549.

15. Alvarado-Esquivel C, Garcia-Corral N, Carrero-Dominguez D et al. Molecular analysis of Mycobacterium isolates from extrapulmonary specimens obtained from patients in Mexico. BMC Clin Pathol. 2009; 9: 1.

16. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959; 43: 273-290.

17. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175: 367-416.

18. Davies P. The mycobacterioses. Imaging. 2008; 20: 252-263.

19. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect. 2009; 15: 906-910.

20. Blackwell V. Mycobacterium marinum infections. Curr Opin Infect Dis. 1999; 12: 181-184.

21. Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg. 2008; 102: 969-978.

22. Ross BC, Johnson PD, Oppedisano F et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol. 1997; 63: 4135-4138.

23. Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev. 1996; 9: 435-447.

24. Brown BA, Springer B, Steingrube VA et al. Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial taxonomy. Int J Syst Bacteriol. 1999; 49 Pt 4: 1493-1511.

25. Viana-Niero C, Lima KV, Lopes ML et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol. 2008; 46: 850-855.

26. Katoch VM. Infections due to non-tuberculous mycobacteria (NTM). Indian J Med Res. 2004; 120: 290-304.

27. Witteck A, Ohlschlegel C, Boggian K. Delayed diagnosis of atypical mycobacterial skin and soft tissue infections in non-immunocompromized hosts. Scand J Infect Dis. 2008; 40: 877-880.

28. Santa Cruz DJ, Strayer DS. The histologic spectrum of the cutaneous mycobacterioses. Hum Pathol. 1982; 13: 485-495.

29. Lipsky BA, Gates J, Tenover FC, Plorde JJ. Factors affecting the clinical value of microscopy for acid-fast bacilli. Rev Infect Dis. 1984; 6: 214-222.

30. Peterson EM, Nakasone A, Platon-DeLeon JM, Jang Y, de La Maza LM, Desmond E. Comparison of direct and concentrated acid-fast smears to identify specimens culture positive for Mycobacterium spp. J Clin Microbiol. 1999; 37: 3564-3568.

31. Salfinger M, Pfyffer GE. The new diagnostic mycobacteriology laboratory. Eur J Clin Microbiol Infect Dis. 1994; 13: 961-979.

32. Ackerman A. Atypical mycobacterial ⁄ deep fungal infections. In: Ackerman A, ed. Histologic diagnosis of inflammatory skin disease. 2nd ed. Baltimore: Williams & Wilkins; 1997. pp. 215-225.

33. Kent P, Kubica G. Public health mycobacteriology. A guide for a level III laboratory. Atlanta: Centers for Disease Control and Prevention 1985.

34. Somoskovi A, Mester J, Hale YM, Parsons LM, Salfinger M. Laboratory diagnosis of nontuberculous mycobacteria. Clin Chest Med. 2002; 23: 585-597.

35. Somoskovi A, Hotaling JE, Fitzgerald M, O’Donnell D, Parsons LM, Salfinger M. Lessons from a proficiency testing event for acid-fast microscopy. Chest. 2001; 120: 250-257.

36. Kinyoun JJ. A note on uhlenhuths method for sputum examination, for Tubercle bacilli. Am J Public Health (NY). 1915; 5: 867-870.

37. Weitzul S, Eichhorn PJ, Pandya AG. Nontuberculous mycobacterial infections of the skin. Dermatol Clin. 2000; 18: 359-377, xi-xii.

38. Abdalla CM, de Oliveira ZN, Sotto MN, Leite KR, Canavez FC, de Carvalho CM. Polymerase chain reaction compared to other laboratory findings and to clinical evaluation in the diagnosis of cutaneous tuberculosis and atypical mycobacteria skin infection. Int J Dermatol. 2009; 48: 27-35.

39. Smith MB, Schnadig VJ, Boyars MC, Woods GL. Clinical and pathologic features of Mycobacterium fortuitum infections. An emerging pathogen in patients with AIDS. Am J Clin Pathol. 2001;116:225-32.

40. Anargyros P, Astill DS, Lim IS. Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J Clin Microbiol. 1990; 28: 1288-1291.

41. Gluckman SJ. Mycobacterium marinum. Clin Dermatol. 1995; 13: 273-276.

42. Ang P, Rattana-Apiromyakij N, Goh CL. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol. 2000; 39: 343-347.

43. Evans KD, Nakasone AS, Sutherland PA, de la Maza LM, Peterson EM. Identification of Mycobacterium tuberculosis and Mycobacterium avium-M. intracellulare directly from primary BACTEC cultures by using acridinium-ester-labeled DNA probes. J Clin Microbiol. 1992; 30: 2427-2431.

44. Clarridge JE, 3rd. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev. 2004; 17: 840-862, table of contents.

45. Cheng MY, Hartl FU, Martin J et al. Mitochondrial heat-shock protein hsp60 is essential for assembly of proteins imported into yeast mitochondria. Nature. 1989; 337: 620-625.

46. Adekambi T, Drancourt M, Raoult D. The rpoB gene as a tool for clinical microbiologists. Trends Microbiol. 2009; 17: 37-45.

47. Dong Y, Demaria S, Sun X et al. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun. 2004; 72: 2412-2415.

48. Murillo J, Torres J, Bofill L et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group. Arch Dermatol. 2000; 136: 1347-1352.

49. Esteban J, Garcia-Pedrazuela M, Munoz-Egea MC, Alcaide F. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother. 2012; 13: 967-986.

50. Lim JM, Kim JH, Yang HJ. Management of infections with rapidly growing mycobacteria after unexpected complications of skin and subcutaneous surgical procedures. Arch Plast Surg. 2012; 39: 18-24.

51. Muthusami JC, Vyas FL, Mukundan U, Jesudason MR, Govil S, Jesudason SR. Mycobacterium fortuitum: an iatrogenic cause of soft tissue infection in surgery. ANZ J Surg. 2004; 74: 662-666.

52. Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother. 1999; 43: 537-542.

53. Van Ingen J, van der Laan T, Dekhuijzen R, Boeree M, van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents. 2010; 35: 169-173.

54. Alcaide F, Calatayud L, Santin M, Martin R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004; 48: 4562-4565.

55. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ, Jr. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2003; 47: 1736-1738.

56. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010; 54: 3678-3685.

57. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F. Buruli ulcer recurrence, Benin. Emerg Infect Dis. 2005; 11: 584-589.

58. Esteban J, Ortiz-Perez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother. 2009; 10: 2787-2799.

59. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012; 67: 810-818.

60. Aubry A, Jarlier V, Escolano S, Truffot-Pernot C, Cambau E. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother. 2000; 44: 3133-3136.

61. Dolenc-Voljc M, Zolnir-Dovc M. Delayed diagnosis of Mycobacterium marinum infection: A case report and review of the literature. Acta Dermatovenerol Alp Panonica Adriat. 2010; 19: 35-39.

62. Parrish N, Luethke R, Dionne K, Carroll K, Riedel S. Case of Mycobacterium marinum infection with unusual patterns of susceptibility to commonly used antibiotics. J Clin Microbiol. 2011; 49: 2056-2058.